New book by Larry Connors Click here Improve your trading - See how
The Governor and Company of the Bank of Ireland (NYSE: IRE | Quote | Chart | News | PowerRating) provides banking and other financial services to small and medium-sized commercial and industrial companies primarily in Ireland, the United Kingdom, the United States, and the rest of world. Its personal banking services include savings and current accounts, credit cards, and mortgages, as well as loans comprising personal loans, motor loans, holiday loans, and graduate loans. The company's student banking services comprise primary banking, school banking, college banking, and graduate banking. Its business banking services consists of business start up packages, franchising, and developing business loans; commercial business cards, deposit options, current accounts, pension products, savings and investments, protection products; and asset finance, including leasing and hire purchase, and commercial finance. The company's capital markets services include corporate banking, foreign exchange, treasury services, asset management, corporate finance, property finance, project finance, and securities services. The Governor and Company of the Bank of Ireland was founded in 1783 and is headquartered in Dublin, Ireland. With 239.75 million shares outstanding and 491,900 shares declared short as of July 2008, there is a failure to deliver in shares of IRE. According to quarterly data provided by the SEC, there were still 14,745 shares of IRE that were failing-to-deliver as of September 24, 2007.
Thornburg Mortgage Inc. (NYSE: TMA | Quote | Chart | News | PowerRating) operates as a residential mortgage lending company. It originates, acquires, and retains investments in adjustable and variable rate mortgage (ARM) assets. The company's ARM assets consist of purchased ARM assets and ARM loans, including traditional ARM assets and hybrid ARM assets. It acquires and originates assets, through correspondent lending, wholesale lending, direct retail lending, and bulk acquisition programs. Thornburg Mortgage, Inc. acquires ARM assets from investment banking firms, broker-dealers, mortgage bankers, mortgage brokerage firms, banks, savings and loan institutions, credit unions, home builders, and other entities involved in originating, securitizing, packaging, and selling mortgage-backed securities and mortgage loans. It operates as an externally advised real estate investment trust (REIT). As a REIT, the company would not be subject to federal corporate income tax, provided it distributes at least 90% of taxable income to its shareholders. Thornburg Mortgage, Inc. was founded in 1992 and is based in Santa Fe, New Mexico. With 386.92 million shares outstanding and 19.56 million shares declared short as of July 2008, there is a failure to deliver in shares of TMA. According to quarterly data provided by the SEC, there were still 879,739 shares of TMA that were failing-to-deliver as of September 28, 2007.
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX | Quote | Chart | News | PowerRating) a biotechnology company, engages in the design, optimization, and development of novel drugs that block enzymes involved in cancer, viral infections, cardiovascular diseases, and autoimmune diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to use structure-based drug design to discover and develop small molecule pharmaceuticals. Its products include forodesine HCl, a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP), which is in Phase IIb trial for patients with Cutaneous T-cell Lymphoma (CTCL), and in a Phase II trial with an oral formulation in Chronic Lymphocytic Leukemia (CLL). The company's forodesine HCl product is used for three indications: T-cell non-Hodgkin lymphoma, including CTCL; CLL and related leukemias, including T-cell prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia; and for treatment of B-cell acute lymphoblastic leukemia. It also develops peramivir, an inhibitor of influenza neuraminidase, which is in Phase II clinical trial for the treatment of influenza with two parenteral formulations, intramuscular, and intravenous; and BCX-4208/R3421, a second generation PNP inhibitor, which is in Phase II clinical trial for the prevention of acute rejection in transplantation and for the treatment of autoimmune diseases. It has collaborative and other research and development contracts with Shionogi & Co., Ltd.; U.S. Department of Health and Human Services; Green Cross Corporation; Mundipharma International Holdings Limited; F.Hoffmann-La Roche, Ltd.; Hoffman-La Roche, Inc.; Albert Einstein College of Medicine of Yeshiva University; Industrial Research, Ltd.; The University of Alabama; Emory University; and Novartis Corporation. The company was founded in 1986 and is based in Birmingham, Alabama. With 38.08 million shares outstanding and 2.21 million shares declared short as of July 2008, there is a failure to deliver in shares of BCRX. According to quarterly data provided by the SEC, there were still 35,976 shares of BCRX that were failing-to-deliver as of September 28, 2007.
M B T Financial Corp (NASDAQ: MBTF | Quote | Chart | News | PowerRating) operates as the holding company for Monroe Bank & Trust that provides customary retail and commercial banking, and trust services in Michigan. It offers various deposit products, including checking and savings accounts, time deposits, NOW accounts, money market deposits, certificates of deposit, and individual retirement accounts. The company's loan portfolio comprises commercial, personal, real estate mortgage, and installment loans. It also provides automated teller machine and night depository facilities, safe deposit facilities, treasury management services, telephone and Internet banking, personal trust, employee benefit, and investment management services. The company serves primarily small and middle-market businesses, and middle-income individuals. As of December 31, 2007, it operated 22 offices and a mortgage loan office in Monroe County, Michigan; and 4 offices in Wayne County, Michigan. The company was founded in 1858 and is headquartered in Monroe, Michigan. With 16.13 million shares outstanding and 250,600 shares declared short as of July 2008, there is a failure to deliver in shares of MBTF. According to quarterly data provided by the SEC, there were still 28,556 shares of MBTF that were failing-to-deliver as of September 4, 2007.
Progen Pharmaceuticals Ltd. (NASDAQ: PGLA | Quote | Chart | News | PowerRating) is a globally focused biotechnology company committed to the discovery, development and commercialization of small molecule pharmaceuticals primarily for the treatment of cancer. Progen has built a focus and strength in anti-cancer drug discovery and development. Progen targets the multiple mechanisms of cancer across its three technology platforms, angiogenesis, epigenetics and cell proliferation. Progen has operations in Australia and the US. With 59.42 million shares outstanding and 7,000 shares declared short as of July 2008, there is a failure to deliver in shares of PGLA. According to quarterly data provided by the SEC, there were still 110,002 shares of PGLA that were failing-to-deliver as of September 28, 2007.
Pharmasset Inc. (NASDAQ: VRUS | Quote | Chart | News | PowerRating) a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing drugs to treat viral infections. Its primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). The company has three product candidates under development, which include Clevudine, an oral, once-daily pyrimidine nucleoside analog, which is under Phase III clinical trials for the treatment of chronic HBV infection; R7128, a pro-drug of PSI-6130 in Part 3 of a Phase I clinical trial for the treatment of HCV, through a collaboration with F. Hoffmann-LaRoche, Ltd. and Hoffmann-La Roche, Inc.; and Racivir, an oral, once-daily cytidine nucleoside analog, which has completed a Phase II clinical trial for the treatment of HIV. In addition, the company engages in the development of DFC, an oral, once-daily deoxycytidine nucleoside analog, for the treatment of HIV. Pharmasset, Inc. was founded in 1998 and is headquartered in Princeton, New Jersey. With 21.59 million shares outstanding and 2.07 million shares declared short as of July 2008, there is a failure to deliver in shares of VRUS.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2,100,000,000 short sale transactions goes back to January 1, 2005, and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005, because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
CONTACT: Thomas Ronk, CEO, BUYINS.NET Tel: +1 800 715 9999 e-mail: Tom@buyins.net WWW: http://www.buyins.net
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
